Eileen DiFrancesco, MD, has built a distinguished career spanning more than 30 years in psychiatry, earning recognition for her expertise in neuropsychiatry, psychopharmacology, integrative psychiatry, and comprehensive diagnostic evaluation. As the founder of DiFrancesco MD LLC, she is dedicated to providing individualized psychiatric care that emphasizes accurate diagnosis, compassionate treatment, and the promotion of long-term brain health.

Dr. DiFrancesco is board certified in Psychiatry by the American Board of Psychiatry and Neurology. She provides comprehensive psychiatric consultation by obtaining detailed developmental, psychiatric, neurological, medical, family, genetic, lifestyle, and environmental histories to develop an accurate diagnosis and individualized treatment plan. She believes that accurate diagnosis is the cornerstone of effective psychiatric care and devotes the time necessary to fully understand each patient's unique clinical presentation.

Her clinical expertise includes psychopharmacology, neuropsychiatry, addiction medicine, mood and anxiety disorders, obsessive-compulsive disorder, bipolar disorder, and complex diagnostic presentations. She is also engaged in evidence-informed research and clinical interest involving emerging metabolic and peptide-based therapies while recognizing that these evolving areas require continued scientific investigation before widespread clinical adoption.

Dr. DiFrancesco earned a Bachelor of Science in Psychology with a pre-medical concentration from the University of Pennsylvania, graduating with honors, before receiving her Doctor of Medicine from Temple University School of Medicine. She completed a residency in Neurology at Hahnemann University (now part of Drexel University), followed by a residency in Psychiatry at Mount Sinai Hospital in New York City. She also completed advanced training in addictive diseases through Rockefeller University, further expanding her expertise in the treatment of complex psychiatric disorders.

Throughout her career, Dr. DiFrancesco has served in several leadership roles. She was Medical Director of the Learning Laboratory in Connecticut, where she specialized in the diagnosis and treatment of attention-deficit disorders, addiction, depression, and bipolar disorder, incorporating Quantitative Electroencephalography (QEEG), also known as brain mapping, as one component of a comprehensive clinical assessment. Earlier in her career, she contributed her diagnostic expertise at the Mount Sinai School of Medicine by evaluating adolescents experiencing psychosis for schizophrenia treatment and research protocols. Throughout her career, her work has consistently focused on helping individuals with complex psychiatric illnesses achieve meaningful improvements in quality of life through thoughtful, evidence-informed care.

In addition to her private practice, Dr. DiFrancesco volunteers with Fountain House, providing psychiatric services to individuals experiencing homelessness and severe mental illness. She remains deeply committed to expanding access to compassionate, high-quality mental healthcare for vulnerable populations.

Her professional accomplishments have been recognized with numerous honors, including IAOTP Top Psychiatrist of the Year in Integrative and Peptide Therapy for 2026, IAOTP Medical Doctor of the Year in Psychiatry and Neurology, the Vitals Most Compassionate Doctor Award, and the Patients' Choice Award, among other professional recognitions.

Outside of medicine, Dr. DiFrancesco enjoys traveling and spending time with her family. She credits her mentor, Dr. E. Roy John, the pioneer of Quantitative Electroencephalography (QEEG), for inspiring her lifelong interest in brain mapping and neuroscience. She also expresses heartfelt appreciation to her brother, John DiFrancesco, whose lifelong resilience has strengthened her commitment to improving the lives of individuals living with complex neuropsychiatric conditions.

Looking ahead, Dr. DiFrancesco plans to continue expanding her clinical, educational, and integrative psychiatry initiatives while advancing evidence-informed approaches to brain health and emerging metabolic and peptide-based therapies. Guided by the belief that optimizing brain health is fundamental to overall well-being, she remains committed to providing individualized, compassionate care and ensuring that every patient receives the time and attention necessary for an accurate diagnosis and meaningful treatment.